ERBB2 and neoplasm: Various combination strategies and other therapies such as the monoclonal antibody margetuximab and three other anti-HER2 ADCs (trastuzumab duocarmazine, disitamab vedotin and MRG002) are also currently being investigated for their safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity [26,27,28,29,30].